Comparison of home fortification with two iron formulations among Kenyan children: Rationale and design of a placebo-controlled non-inferiority trial

Contemporary Clinical Trials Communications

Volumn 7, Issue , 2017, Pages 1-10

  Teshome, Emily M ^a,b   Otieno, Walter ^c   Terwel, Sofie R ^d   Osoti, Victor ^e   Demir, Ayşe Y ^f   Andango, Pauline E A ^c   Prentice, Andrew M ^a,b   Verhoef, Hans ^a,b,d  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c MASENO UNIVERSITY   (Kenya)

^d WAGENINGEN UNIVERSITY   (Netherlands)

^e INTERNATIONAL CENTRE OF INSECT PHYSIOLOGY AND ECOLOGY ICIPE   (Kenya)

^f MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Anaemia; Child; Dietary supplements; Fortification; Iron; Non inferiority; Preschool

Indexed keywords

ANTIMALARIAL AGENT; FERROUS FUMARATE; HEMOGLOBIN; HEPCIDIN; IRON; PLACEBO;

ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; CHILD; CHILD NUTRITION; CLINICAL OUTCOME; CONTROLLED STUDY; ENCAPSULATION; FOLLOW UP; FORTIFIED FOOD; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION PREVENTION; KENYAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MINERAL SUPPLEMENTATION; PATIENT COMPLIANCE; PLASMODIUM MALARIAE INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN;

EID: 85019019920     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2017.04.007     Document Type: Article

References (52)

1. [1] WHO Guideline: Use of Multiple Micronutrient Powders for Point-of-use Fortification of Foods Consumed by Infants and Young Children Aged 6–23 Months and Children Aged 2–12 Years, 2016, World Health Organization, Geneva, Switzerland Available at: http://apps.who.int/iris/bitstream/10665/252540/1/9789241549943-eng.pdf?ua=1 (Accessed 6 February 2017).
2. [2] De Benoist, B., McLean, E., Egli, I., Cogswell, M., (eds.) Worldwide Prevalence of Anaemia 1993-2005: WHO Global Database on Anaemia, 2008, World Health Organization, Geneva, Switzerland Available at: http://apps.who.int/iris/bitstream/10665/43894/1/9789241596657_eng.pdf (Accessed 6 February 2017).
3. [3] Nestel, P., Alnwick, D., for the International Nutritional Anaemia Consultative Group (INACG). Iron/multi-micronutrient Supplements for Young Children: Summary and Conclusions of a Consultation Held at UNICEF, Copenhagen, August 19–20, 1996. 1997, ILSI Human Nutrition Institute, Washington DC, USA Available at: http://ilsirf.org/wp-content/uploads/sites/5/2016/04/INACG_Iron_Multi-Micronutrient_Supplement-for-Young-Children.pdf (Accessed 6 February 2017).
4. [4] Paganini, D., Uyoga, M.A., Zimmermann, M.B., Iron fortification of foods for infants and children in low-income countries: effects on the gut microbiome, gut inflammation, and diarrhea. Nutrients, 8(8), 2016, 494.
5. [5] WHO, UNICEF, UNU, Iron Deficiency Anaemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Document Reference WHO/NHD/01.3. 2001, World Health Organization, Geneva Available at: http://apps.who.int/iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf?ua=1 (Accessed 6 February 2017).
6. [6] Troesch, B., Egli, I., Zeder, C., Hurrell, R.F., de Pee, S., Zimmermann, M.B., Optimization of a phytase-containing micronutrient powder with low amounts of highly bioavailable iron for in-home fortification of complementary foods. Am. J. Clin. Nutr. 89:2 (2009), 539–544.
7. [7] Verhoef, H., Veenemans, J., Safety of iron-fortified foods in malaria-endemic areas. Am. J. Clin. Nutr. 89:6 (2009), 1949–1950.
8. [8] Soofi, S., Cousens, S., Iqbal, S.P., Akhund, T., Khan, J., Ahmed, I., Zaidi, A.K., et al. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. Lancet 382:9886 (2013), 29–40.
9. [9] World Health Organization Secretariat on behalf of the participants of the Consultation. Conclusions and recommendations of the WHO Consultation on prevention and control of iron deficiency in infants and young children in malaria-endemic areas. Food Nutr. Bull. 28:4 Suppl (2007), S621–S627.
10. [10] Veenemans, J., Milligan, P., Prentice, A.M., Schouten, L.R., Inja, N., van der Heijden, A.C., et al. Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial. PLoS Med., 8(11), 2011, e1001125.
11. [11] Goheen, M.M., Wegmüller, R., Bah, A., Darboe, B., Danso, E., Affara, M., et al. Anemia offers stronger protection than sickle cell trait against the erythrocytic stage of falciparum malaria and this protection is reversed by iron supplementation. EBioMedicine 14 (2016), 123–130.
12. [12] Government of Kenya (GoK). Kisumu district strategic plan 2005-2010 for implementation of the national population policy for sustainable development.
13. [13] Government of Kenya (GoK), Ministry of Public Health and Sanitation, Malaria indicator survey (KMIS) report 2010. Available at: https://dhsprogram.com/pubs/pdf/MIS7/MIS7.pdf (Accessed 6 February 2017).
14. [14] Mwangi, M.N., Roth, J.M., Smit, M.R., Trijsburg, L., Mwangi, A.M., Demir, A.Y., et al. Effect of daily antenatal iron supplementation on Plasmodium infection in Kenyan women: a randomized clinical trial. JAMA 314:10 (2015), 1009–1020.
15. [15] Munyekenye, O.G., Githeko, A.K., Zhou, G., Mushinzimana, E., Minakawa, N., Yan, G., Plasmodium falciparum spatial analysis, western Kenya highlands. Emerg. Infect. Dis. 11:10 (2005), 1571–1577.
16. [16] Verani, J.R., Abudho, B., Montgomery, S.P., Mwinzi, P.N., Shane, H.L., Butler, S.E., et al. Schistosomiasis among young children in Usoma, Kenya. Am. J. Trop. Med. Hyg. 84:5 (2011), 787–791.
17. [17] Brooker, S., Peshu, N., Warn, P., Mosobo, M., Guyatt, H.L., Marsh, K., et al. The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenya coast. Trans. R. Soc. Trop. Med. Hyg. 93:3 (1999), 240–246.
18. [18] Albonico, M., Allen, H., Chitsulo, L., Engels, D., Gabrielli, A.F., Savioli, L., Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. PLoS Negl. Trop. Dis., 2(3), 2008, e126.
19. [19] D'Agostino, R.B., Massaro, J.M., Sullivan, L.M., Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics. Stat. Med. 22:2 (2003), 169–186.
20. [20] Schumi, J., Wittes, J.T., Through the looking glass: understanding non-inferiority. Trials, 12, 2011, 106.
21. [21] Neuberger, A., Okebe, J., Yahav, D., Paul, M., Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst. Rev., 2, 2016 CD006589.
22. [22] Hastka, J., Lasserre, J., Schwarzbeck, A., Strauch, M., Hehlmann, R., Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry. Clin. Chem. 38:11 (1992), 2184–2189.
23. [23] Preventive chemotherapy in human helminthiasis. Coordinated Use of Antihelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers, 2006, World Health Organization, Geneva, Switzerland Available at: http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf (Accessed 6 February 2017).
24. [24] Verhoef, H., Veenemans, J., Mwangi, M.N., Prentice, A.M., Safety and benefits of interventions to increase folate status in malaria-endemic areas. Br. J. Haematol., 2017, 10.1111/bjh.14618 http://onlinelibrary.wiley.com/doi/10.1111/bjh.14618/full.
25. [25] Cramer, J.A., Mattson, R.H., Prevey, M.L., Scheyer, R.D., Ouellette, V.L., How often is medication taken as prescribed? A novel assessment technique. JAMA 261:22 (1989), 3273–3277.
26. [26] Vrijens, B., Urquhart, J., Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother. 55:5 (2005), 616–627.
27. [27] Olivieri, N.F., Matsui, D., Hermann, C., Koren, G., Compliance assessed by the medication event monitoring system. Arch. Dis. Child. 66:12 (1991), 1399–1402.
28. [28] Grosset, K.A., Bone, I., Reid, J.L., Grosset, D., Measuring therapy adherence in Parkinson's disease: a comparison of methods. J. Neurol. Neurosurg. Psychiatry 77:2 (2006), 249–251.
29. [29] WHO, Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Document Reference WHO/NMH/NHD/MNM/11.1. 2011, World Health Organization, Geneva, Switzerland Available: http://www.who.int/entity/vmnis/indicators/haemoglobin.pdf (Accessed 6 February 2017).
30. [30] Makler, M.T., Palmer, C.J., Ager, A.L., A review of practical techniques for the diagnosis of malaria. Ann. Trop. Med. Parasitol. 92:4 (1998), 419–433.
31. [31] Piper, R., Lebras, J., Wentworth, L., Hunt-Cooke, A., Houzé, S., Chiodini, P., et al. Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase (pLDH). Am. J. Trop. Med. Hyg. 60:1 (1999), 109–118.
32. [32] Moody, A., Rapid diagnostic tests for malaria parasites. Clin. Microbiol. Rev. 15:1 (2002), 66–78.
33. [33] Serum Ferritin Concentrations for the Assessment of Iron Status and Iron Deficiency in Populations. Vitamin and Mineral Nutrition Information System, 2011, World Health Organization, Geneva (WHO/NMH/NHD/MNM/11.2) http://apps.who.int/iris/bitstream/10665/85843/1/WHO_NMH_NHD_MNM_11.2_eng.pdf?ua=1 (Accessed on 6 February 2017).
34. [34] Abraham, K., Muller, C., Gruters, A., Wahn, U., Schweigert, F.J., Minimal inflammation, acute phase response and avoidance of misclassification of vitamin A and iron status in infants—importance of a high-sensitivity C-reactive protein (CRP) assay. Int. J. Vitam. Nutr. Res. 73:6 (2003), 423–430.
35. [35] Ayoya, M.A., Spiekermann-Brouwer, G.M., Stoltzfus, R.J., Nemeth, E., Habicht, J.P., Ganz, T., et al. Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. Am. J. Clin. Nutr. 91:6 (2010), 1784–1790.
36. [36] Wang, Y., Kong, M.C., Ko, Y., Comparison of three medication adherence measures in patients taking warfarin. J. Thromb. Thrombolysis 36:4 (2013), 416–421.
37. [37] Knafl, G.J., Schoenthaler, A., Ogedegbe, G., Secondary analysis of electronically monitored medication adherence data for a cohort of hypertensive African-Americans. Patient Pref. Adherence 6 (2012), 207–219.
38. [38] Shalansky, S.J., Levy, A.R., Ignaszewski, A.P., Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann. Pharmacother. 38:9 (2004), 1363–1368.
39. [39] Ho, P.M., Bryson, C.L., Rumsfeld, J.S., Medication adherence: its importance in cardiovascular outcomes. Circulation 119:23 (2009), 3028–3035.
40. [40] Committee for Proprietary Medicinal Products (CPMP), Points to Consider on Multiplicity Issues in Clinical Trials. CPMP/EWP/908/99. 2002, European Medicine Agency, London, UK Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf (Accessed 6 February 2017).
41. [41] Zongo, I., Milligan, P., Compaore, Y.D., Some, A.F., Greenwood, B., Tarning, J., Rosenthal, P.J., Sutherland, C., Nosten, F., Ouedraogoa, J.-B., Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 59:8 (2015), 4387–4396.
42. [42] Verhoef, H., West, C.E., Nzyuko, S.M., de Vogel, S., van der Valk, R., Wanga, M.A., Kuijsten, A., Veenemans, J., Kok, F.J., Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet 360:9337 (2002), 908–914.
43. [43] Rothman, K.J., Michels, K.B., The continuing unethical use of placebo controls. N. Engl. J. Med. 331:6 (1994), 394–398.
44. [44] Stang, A., Hense, H.W., Jöckel, K.H., Turner, E.H., Tramèr, M.R., Is it always unethical to use a placebo in a clinical trial?. PLoS Med., 2(3), 2005, e72.
45. [45] Rothman, K.J., Placebo mania: as medical knowledge accumulates, the number of placebo trials should fall. BMJ 313 (1996), 3–4.
46. [46] ICH Harmonised tripartite guideline, Choice of control group and related issues in clinical trials E10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2000 Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf (Accessed 6 February 2017).
47. [47] McQuay, H., Moore, A., Placebo mania: placebo are essential when extent and variability of placebo response are unknown. BMJ, 313, 1996, 1008.
48. [48] Senn, S., Ethical considerations concerning treatment allocation in drug development trials. Stat. Methods Med. Res. 11:5 (2002), 403–411.
49. [49] Dmitrienko A, Wiens B. Branching tests in clinical trials with multiple objectives. Available at: http://www.amstat.org/meetings/fdaworkshop/presentations/2005/G5_Dmitrienko_Multiplicity.pdf (accessed 6 February 2017).
50. [50] Schulz, K.F., Grimes, D.A., Multiplicity in randomised trials I: endpoints and treatments. Lancet 365:9470 (2005), 1591–1595.
51. [51] Altman, D.G., Bland, J.M., Absence of evidence is no evidence of absence. BMJ, 311(7003), 1995, 485.
52. [52] Sterne, J.A., Smith Davey, G., Sifting the evidence—what's wrong with significance tests?. BMJ 322:7280 (2001), 226–231.